BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lonitoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lonitoclax\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07303660-3075@assetmemo.bio
DTSTAMP:20261121T005909Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lonitoclax: Phase 1 readout est. (NCT07303660)
DESCRIPTION:Lonitoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lonitoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07303660
URL:https://assetmemo.bio/drug/lonitoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06708897-3075@assetmemo.bio
DTSTAMP:20261121T005909Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Lonitoclax: Phase 1 readout est. (NCT06708897)
DESCRIPTION:Lonitoclax\, phase 1.\nStudy: A Study of Lonitoclax (ZE50-0134)
  in Relapsed or Refractory B-cell Malignancies\nEstimated primary completi
 on: January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lon
 itoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06708897
URL:https://assetmemo.bio/drug/lonitoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
